HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.

Zhou, Yan; Yang, Jiyuan; Rhim, Johng S; Kopecek, Jindrich

Zhou, Yan; Yang, Jiyuan; Rhim, Johng S; Kopecek, Jindrich.

Affiliation

Zhou Y; Department of Pharmaceutics and Pharmaceutical Chemistry/CCCD, University of Utah, Salt Lake City 84112, USA.

J Control Release ; 172(3): 946-53, 2013 Dec 28.

Article in En | MEDLINE | ID: mdl-24041709

Subject(s)

Antineoplastic Agents/therapeutic use; Methacrylates/chemistry; Neoplastic Stem Cells/drug effects; Prostatic Neoplasms/drug therapy; Taxoids/therapeutic use; Veratrum Alkaloids/therapeutic use; Animals; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/chemistry; Cell Differentiation/drug effects; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells/pathology; Prostate/drug effects; Prostate/pathology; Prostatic Neoplasms/pathology; Taxoids/administration & dosage; Taxoids/chemistry; Veratrum Alkaloids/administration & dosage; Veratrum Alkaloids/chemistry

Key words

Cancer stem/progenitor cells; Combination therapy; Cyclopamine; Docetaxel; N-(2-hydroxypropyl)methacrylamide (HPMA)

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Neoplastic Stem Cells / Veratrum Alkaloids / Taxoids / Methacrylates / Antineoplastic Agents Limits: Animals / Humans / Male Language: En Journal: J Control Release Year: 2013 Document type: Article

Fulltext

XML

PubMed Links

Search on Google